Cargando…

Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity

OBJECTIVE: This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks. METHODS: In this phase 3b, randomized, open‐label, controlled study, subjects received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halseth, Amy, Shan, Kevin, Walsh, Brandon, Gilder, Kye, Fujioka, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299461/ https://www.ncbi.nlm.nih.gov/pubmed/28026920 http://dx.doi.org/10.1002/oby.21726

Ejemplares similares

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018)

A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
por: Apovian, Caroline M, et al.
Publicado: (2013)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
por: Hollander, Priscilla, et al.
Publicado: (2013)

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
por: Guerdjikova, Anna I., et al.
Publicado: (2017)

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Buehler, Anna M
Publicado: (2015)

The use of bupropion SR in cigarette smoking cessation
por: Wilkes, Scott
Publicado: (2008)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
por: Dahlberg, Sarah, et al.
Publicado: (2022)

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives
por: Tek, Cenk
Publicado: (2016)

The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy
por: le Roux, Carel W., et al.
Publicado: (2022)

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
por: Lyu, Xuechan, et al.
Publicado: (2018)

Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial
por: Reimherr, Frederick W, et al.
Publicado: (2005)

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats
por: Scudeler, Monica Alhadas, et al.
Publicado: (2022)

Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures
por: Siamidi, Angeliki, et al.
Publicado: (2021)

Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
por: Wang, Gene-Jack, et al.
Publicado: (2018)

Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo
por: Gonzales, David, et al.
Publicado: (2010)

Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues
por: Wang, G-J, et al.
Publicado: (2014)

Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity
por: Welling, Mila S., et al.
Publicado: (2023)

Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
por: Pi-Sunyer, Xavier, et al.
Publicado: (2019)

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study
por: McElroy, Susan L., et al.
Publicado: (2013)

Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
por: Zhao, Yujin, et al.
Publicado: (2022)

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
por: Cho, A-Ra, et al.
Publicado: (2020)

Evaluation and identification of stem rust resistance genes Sr2, Sr24, Sr25, Sr26, Sr31 and Sr38 in wheat lines from Gansu Province in China
por: Xu, Xiao Feng, et al.
Publicado: (2017)

The wheat Sr22, Sr33, Sr35 and Sr45 genes confer resistance against stem rust in barley
por: Hatta, M. Asyraf Md, et al.
Publicado: (2020)

Role of Bupropion and Naltrexone in Managing Depression With Polycystic Ovary Syndrome: A Case Report and Literature Review
por: Shah, Kaushal, et al.
Publicado: (2020)

Simultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
por: Abdel-Gawad, Sherif A., et al.
Publicado: (2018)

Assessment of the effectiveness of sustained release Bupropion and intensive physician advice in smoking cessation
por: Singh, Pranav, et al.
Publicado: (2010)

Identification of ER/SR resident proteins as biomarkers for ER/SR calcium depletion in skeletal muscle cells
por: Greer, Lacey K., et al.
Publicado: (2022)

Transportin-SR, a Nuclear Import Receptor for SR Proteins
por: Kataoka, Naoyuki, et al.
Publicado: (1999)

Identical transitions in the strongly deformed Sr-99 and Sr-100
por: Lhersonneau, G., et al.
Publicado: (2001)

(2SR,4aSR,8aSR)-6-Oxoperhydronaphthalene-2-carboxylic acid
por: Efthimiopoulos, Georgia, et al.
Publicado: (2008)

Electronic properties and surface reactivity of SrO-terminated SrTiO(3) and SrO-terminated iron-doped SrTiO(3)
por: Staykov, Aleksandar, et al.
Publicado: (2018)

Reduction in Obesity-Related Hepatic Fibrosis by SR1664
por: McVicker, Benita L., et al.
Publicado: (2023)

A prebreeding study of introgression spring bread wheat lines carrying combinations of stem rust resistance genes, Sr22+Sr25 and Sr35+Sr25
por: Sibikeev, S.N., et al.
Publicado: (2021)

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial
por: Wharton, Sean, et al.
Publicado: (2021)

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
por: Smith, Steve R., et al.
Publicado: (2008)

The SR finds the translocon
por: LeBrasseur, Nicole
Publicado: (2008)

The SR protein family
por: Shepard, Peter J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_9pqthe5cff8d63vs5v5tp17m2c